Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 07/23 11:30:30 am
84.57 CHF   +0.89%
07:20aNOVARTIS AG : Buy rating from UBS
MD
07/22GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
07/22GLAXOSMITHKLINE : GSK appoints consumer head as CEO of new spin-off
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline

06/18/2021 | 12:30pm EDT

(MORE TO FOLLOW) Dow Jones Newswires

June 18, 2021 12:30 ET (16:30 GMT)

All news about NOVARTIS AG
07:20aNOVARTIS AG : Buy rating from UBS
MD
07/22GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
07/22GLAXOSMITHKLINE : GSK appoints consumer head as CEO of new spin-off
RE
07/22NOVARTIS AG : Deutsche Bank is now Neutral
MD
07/22ANALYST RECOMMENDATIONS : Barclays, Chevron, Flutter, Netflix, Unilever...
07/22NOVARTIS AG : Credit Suisse sticks Neutral
MD
07/22NOVARTIS : ESG Update - July 22, 2021
PU
07/22NOVARTIS AG : Goldman Sachs remains its Buy rating
MD
07/21NOVARTIS AG : Bernstein sticks Neutral
MD
07/21European Stocks Close in Green On Strong Earnings
MT
More news
Financials (USD)
Sales 2021 51 952 M - -
Net income 2021 9 749 M - -
Net Debt 2021 24 013 M - -
P/E ratio 2021 20,0x
Yield 2021 3,63%
Capitalization 222 B 222 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,41x
Nbr of Employees 109 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 91,14 $
Average target price 105,30 $
Spread / Average Target 15,5%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG0.20%207 246
JOHNSON & JOHNSON8.01%432 430
ROCHE HOLDING AG11.02%325 975
PFIZER, INC.12.66%218 198
ELI LILLY AND COMPANY41.25%209 276
ABBVIE INC.9.70%199 548